Diseased Human Peripheral Blood Products, Hematological Cancer
Primary human cells, frozen
Diseased Human Peripheral Blood Products, Hematological Cancer
Primary human cells, frozen
Overview
Start immuno-oncology experiments confidently with a reliable supply of ethically sourced, custom-isolated frozen peripheral blood plasma and serum from donors diagnosed with a hematological cancer.
Primary human plasma is isolated from peripheral blood using centrifugation. Primary human serum is isolated from peripheral blood after coagulation and removal of the fibrin clot and blood cells. All frozen peripheral blood products are obtained from donors diagnosed with a hematological cancer using Institutional Review Board (IRB)-approved consent forms and protocols. Additional documentation to meet institutional requirements is available upon request. Acid-citrate-dextrose (ACD), acid-citrate-dextrose solution A (ACDA), citrate-phosphate-dextrose (CPD), citrate-phosphate-double-dextrose (CP2D), or citrate-phosphate-dextrose-adenine (CPDA) is added during collection as an anticoagulant.
Contact your local sales representative or Product & Scientific Support at techsupport@stemcell.com for donor specifications (BMI category, smoking status, ethnicity, etc.). Donors are screened for HIV-1, HIV-2, hepatitis B, and hepatitis C. Certain products are only available in select territories.
For more information, browse frequently asked questions (FAQs) on primary cells.
Primary human plasma is isolated from peripheral blood using centrifugation. Primary human serum is isolated from peripheral blood after coagulation and removal of the fibrin clot and blood cells. All frozen peripheral blood products are obtained from donors diagnosed with a hematological cancer using Institutional Review Board (IRB)-approved consent forms and protocols. Additional documentation to meet institutional requirements is available upon request. Acid-citrate-dextrose (ACD), acid-citrate-dextrose solution A (ACDA), citrate-phosphate-dextrose (CPD), citrate-phosphate-double-dextrose (CP2D), or citrate-phosphate-dextrose-adenine (CPDA) is added during collection as an anticoagulant.
Contact your local sales representative or Product & Scientific Support at techsupport@stemcell.com for donor specifications (BMI category, smoking status, ethnicity, etc.). Donors are screened for HIV-1, HIV-2, hepatitis B, and hepatitis C. Certain products are only available in select territories.
For more information, browse frequently asked questions (FAQs) on primary cells.
Subtype
Frozen
Species
Human
Cell and Tissue Source
Plasma, Serum
Area of Interest
Cancer, Drug Discovery and Toxicity Testing, Stem Cell Biology
Donor Status
Diseased
Protocols and Documentation
Find supporting information and directions for use in the Product Information Sheet or explore additional protocols below.
Document Type
Product Name
Catalog #
Lot #
Language
Document Type
Product Information Sheet
Product Name
Hematological Cancer, Custom, Frozen
Catalog #
200-0404 Lot #
All Language
English Applications
This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.
Research Area
Workflow Stages
Workflow Stages for
B Cell Research
Workflow Stages for
Dendritic Cell Research
Workflow Stages for
Hematopoietic Stem and Progenitor Cell Research
Workflow Stages for
HLA Analysis
Workflow Stages for
Innate Lymphoid Cell Research
Workflow Stages for
Monocyte Research
Workflow Stages for
Natural Killer Cell Research
Workflow Stages for
T Cell Research
Workflow Stages for
T Cell Engineering
Workflow Stages for
Total Lymphocyte Research
Workflow Stages for
Extracellular Vesicle Research
Resources and Publications
Educational Materials (4)
Quality Statement:
PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED. FOR ADDITIONAL INFORMATION ON QUALITY AT STEMCELL, REFER TO WWW.STEMCELL.COM/COMPLIANCE.
